Gliclazide

Acta Crystallographica Section C: Crystal Structure Communications

Volumn 55, Issue 1, 1999, Pages 74-75

  Parvez, Masood ^a   Saeed Arayne, M ^b   Kamran Zaman, M ^b   Sultana, Najma ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4243978552     PISSN: 01082701     EISSN: None     Source Type: Journal    
DOI: 10.1107/S0108270198009883     Document Type: Article

References (13)

1. Enraf-Nonius (1989). CAD-4 Software. Version 5.0. Enraf-Nonius, Delft, The Netherlands.
2. Fan, H.-F. (1991). SAPI91. Structure Analysis Program with Intelligent Control. Rigaku Corporation, Tokyo, Japan.
3. Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
4. Kamenar, B., Matkovic, D. & Nagl, A. (1983). Croat. Chem. Acta, 56, 87-95.
5. Koo, C. H., Suh, J. S., Yeon, Y. H. & Watanabe, T. (1988). Arch. Pharm. Res. 11, 74-79.
6. Lebovitz, H. E. & Feinglos, M. N. (1983). Diabetes Mellitus: Theory and Practices, 3rd ed., edited by M. Ellenberg & H. Rifkin, pp. 591-610. New York: Medical Examination Publishing.
7. Long, J. W. (1990). The Essential Guide to Prescription Drugs, pp. 505-509. New York: Harper & Row.
8. Molecular Structure Corporation (1994). TEXSAN. Single Crystal Structure Analysis Software. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
9. North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). Acta Cryst. A24, 351-359.
10. Reynolds, J. E. F. (1994). Martindale: The Extra Pharmacopoeia, 13th ed., p. 279. London: Info Access & Distribution Pte Ltd.
11. Sheldrick, G. M. (1997). SHELXL97. Program for the Refinement of Crystal Structures. University of Göttingen, Germany.
12. Stockley, I. H. (1991). Drug Interactions, 2nd ed., pp. 417-126. London: Blackwell Scientific Publication.
13. Webster, J. M. & Taylor, R. (1996). Diab. Nutr. Metab. 9, 115-121.